FibroGen announces publication of results from Phase 1 study of FG-3246
FibroGen (FGEN) announced the peer-reviewed publication titled “A Phase 1, First-in-Human Study of FOR46, an Immune-Modulating Antibody-Drug ...
Fierce Biotech9d
Regulatory T-cell therapy calms autoimmune response from gluten-sensitive T cells in mice
For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. | For the 80 million people worldwide who have celiac ...
EurekAlert!3d
PP2A regulates CD8+ T cell effector functions through AKT signaling pathway: implications for immunotherapy
A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...
Hosted on MSN18d
T-Cell Rebalancing Therapy Active in Previously Treated Atopic Dermatitis
OX40R is a co-stimulatory molecule expressed on activated effector and memory T cells, and OX40R-positive T cells release pro-inflammatory cytokines that drive memory responses in AD. The number and ...
CURE7d
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...
Hospital Healthcare Europe1d
IgE therapy shows promise for treatment-resistant breast and ovarian cancers
A new anti-HER2 IgE antibody potentially offers new therapy options for treatment-resistant breast and ovarian cancers.
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual MeetingPre-clinical data on Medicenna’s first-in-class Masked and ...